drugset / Trial / NCT00396656

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

NCT00396656

Phase 3 Completed 30 enrolled Novartis
RandomizedCrossoverOpen-labelTreatment

Summary

This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.

Timeline

Start
2005-12
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Atenolol Other / unclassified 100 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral
Subject Valsartan Small molecule 320 mg Oral

Indications